Page 65 - Read Online

Page 14 of 16 Zhang et al. Neuroimmunol Neuroinflammation 2019;6:8 I http://dx.doi.org/10.20517/2347-8659.2019.06

111. Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, et al. Randomized placebo-controlled trial of mitoxantrone in
relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-9.
112. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting
multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg
Psychiatry 2008;79:52-6.
113. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate
Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013;13:80.
114. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled,
double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25.
115. van de Wyngaert FA, Beguin C, D’Hooghe MB, Dooms G, Lissoir F, et al. A double-blind clinical trial of mitoxantrone versus
methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101:210-6.
116. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple
sclerosis. Neurology 2008;71:1261-7.
117. Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, et al. Fingolimod (FTY720) enhances remyelination following
demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682-94.
118. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008;274:13-7.
119. Kappos L, Radue EW, O’ Connor P, Polman C, Hohlfeld R, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple
sclerosis. N Engl J Med 2010;362:387-401.
120. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, et al. Safety and efficacy of fingolimod in patients with relapsing-
remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol
2014;13:545-56.
121. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting
multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9.
122. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients
with multiple sclerosis. Mult Scler 2012;18:1269-77.
123. Ordoñez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, et al. Safety and tolerability of fingolimod in Latin American patients with
relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study. Adv Ther 2015;32:626-35.
124. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis:
results from the extension of the randomized TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016;87:468-75.
125. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, et al. Oral fingolimod in primary progressive multiple sclerosis
(INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1075-84.
126. Papadopoulou A, Kappos L, Sprenger T. Teriflunomide for oral therapy in multiple sclerosis. Expert Rev Clin Pharmacol 2012;5:617-28.
127. Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS
autoimmune pathogenesis. Eur J Immunol 2016;46:2078-90.
128. Confavreux C, O’ Connor P, Comi G, Freedman MS, Miller AE, et al. Oral teriflunomide for patients with relapsing multiple scle-rosis
(TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56.
129. O’ Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, et al. Randomized trial of oral teriflunomide for relapsing multiple
sclerosis. N Engl J Med 2011;365:1293-303.
130. O’ Connor P, Comi G, Freedman MS, Miller AE, Kappos L, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up
of the randomized TEMSO study. Neurology 2016;86:920-30.
131. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, et al. Teriflunomide versus subcutaneous interferon beta-1a in
patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16.
132. Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol 2014;262:52-6.
133. Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, et al. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale,
mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015;15:339-46.
134. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple
sclerosis. N Engl J Med 2012;367:1098-107.
135. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in
multiple sclerosis. N Engl J Med 2012;367:1087-97.
136. Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, et al. Long-term effects of delayed-release dimethyl fumarate in multiple
sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler 2017 ;23:253-65.
137. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. Prevention of experimental autoimmune encephalomyelitis by
antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-6.
138. Derfuss T, Kuhle J, Lindberg R, Kappos L. Natalizumab therapy for multiple sclerosis. Semin Neurol 2013;33:26-36.
139. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. Natalizumab plus interferon beta-1a for relapsing multiple
sclerosis. N Engl J Med 2006;354:911-23.
140. Polman CH, O’ Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. A randomized, placebo-controlled trial of natalizumab for
relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
141. Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting
multiple sclerosis: resultsfrom a multi-center study in German speaking countries. Eur J Neurol 2010;17:31-7.
142. Outteryck O, Ongagna JC, Zéphir H, Fleury MC, Lacour A, et al. Demographic and clinic characteristics of French patients treated with
natalizumab in clinical practice. J Neurol 2010;257:207-11.
143. Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting